乳腺癌新辅助内分泌治疗的研究进展  

Research progress of neoadjuvant endocrine therapy for breast cancer

作　　者：莫一敏 吴骁凡 俞星飞[2] 杨红健[2] Mo Yimin;Wu Xiaofan;Yu Xingfei;Yang Hongjian(The 2nd Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Breast Surgery,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310053 [2]浙江省肿瘤医院乳腺外科中国科学院杭州医学研究所,杭州310022

出　　处：《中华内分泌外科杂志（中英文）》2024年第2期313-316,共4页Chinese Journal of Endocrine Surgery

基　　金：浙江省卫生健康科技计划(2022KY670)。

摘　　要：乳腺癌为女性最常见的癌症,对于激素受体(hormone receptor,HR)阳性的乳腺癌患者,新辅助内分泌治疗(neoadjuvant endocrine therapy,NET)是一种有效的治疗策略。本文围绕NET与新辅助化疗(neoadjuvant chemotherapy,NCT)疗效对比、NET联合化疗或靶向治疗、NET的预测指标等方面进行综述。Breast cancer is the most common cancer in women,and neoadjuvant endocrine therapy(NET)is an effective treatment strategy for hormone receptor(HR)-positive breast cancer.This review focuses on the efficacy of NET compared with neoadjuvant chemotherapy(NCT),NET combined with chemotherapy or targeted therapy,and the predictors of NET.

关 键 词：乳腺癌 激素受体阳性 新辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]